- Home
- JKHY vs UTHR Comparison
JKHY vs UTHR Comparison
Compare JKHY & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | UTHR |
|---|---|---|
| Founded | 1976 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.9B | 20.3B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | JKHY | UTHR |
|---|---|---|
| Price | $181.97 | $488.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $176.22 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 823.8K | 424.3K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 20.28 | 16.08 |
| EPS | 6.58 | ★ 26.38 |
| Revenue | $2,419,044,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $6.98 | $13.64 |
| Revenue Next Year | $6.45 | $5.78 |
| P/E Ratio | $27.62 | ★ $18.55 |
| Revenue Growth | 7.75 | ★ 13.50 |
| 52 Week Low | $144.12 | $266.98 |
| 52 Week High | $196.00 | $492.62 |
Technical Indicators
Market Signals| Indicator | JKHY | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 79.13 | 68.10 |
| Support Level | $171.86 | $470.13 |
| Resistance Level | $175.90 | $492.62 |
| Average True Range (ATR) | 3.10 | 10.72 |
| MACD | 0.90 | -0.53 |
| Stochastic Oscillator | 99.21 | 89.55 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.